RecruitingPhase 3NCT05066217
Neurological
Lennox-Gastaut Syndrome
Also known as LGS, childhood epileptic encephalopathy with diffuse slow spike-waves
Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy defined by a triad of multiple seizure types (particularly tonic and atonic drop attacks), characteristic EEG pattern (slow spike-wave and fast rhythms during sleep), and in
ORPHA:2382 ↗Gene Multiple (SCN1AGene STXBP1Gene CDKL5Gene and others)Prevalence 1-5 per 10,000 (Orphanet)Onset Infantile, ChildhoodMultiple etiologies (structural, genetic, metabolic, unknown)
5
studies recruiting now
as of 7 Sept 2026
70
studies registered in total
as of 7 Sept 2026
19
countries with a recruiting site
as of 7 Sept 2026
11 Apr 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT05374824
Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome
RecruitingNot applicableNCT06924086
The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial
RecruitingPhase 2NCT06401538
BMB-101 in Absence Epilepsy and DEE
RecruitingPhase 3NCT05219617
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Lennox-Gastaut Syndrome studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Lennox-Gastaut Syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: Epilepsy Learning Healthcare System (ELHS) · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Lennox-Gastaut Syndrome
Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy defined by a triad of multiple seizure types (particularly tonic and atonic drop attacks), characteristic EEG pattern (slow spike-wave and fast rhythms during sleep), and intellectual disability. It typically emerges between ages 1-8 years and is frequently refractory to antiseizure medications. Cannabidiol (Epidiolex), clobazam, rufinamide, and felbamate have specific approval for LGS.
Common clinical features
Tonic seizuresAtonic drop attacksAbsence seizuresEEG slow spike-wave patternIntellectual disabilityBehavioral problemsFrequent falls and injury
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
5 approved treatments and 5 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Topiramate (Epitomax)Approved: Cannabidiol (Epidiolex)Approved: Lamotrigine (Lamictal)Approved: Clobazam (Frisium)Approved: Rufinamide (Banzel)
Phase 3Clemizole
Phase 3Soticlestat
Phase 3Perampanel (Fycompa)
Phase 3Fenfluramine
Phase 3Carisbamate
Before you apply
Things trial teams commonly ask about for Lennox-Gastaut Syndrome. Not eligibility rules; those are set by each study.
- EEG-confirmed LGS criteria (slow spike-wave <3Hz, tonic seizures, cognitive impairment) must be documented at baseline
- Drop attack (tonic and atonic seizure) frequency diary over minimum 3 months is required for most LGS trials
- Etiology (structural, genetic, unknown) should be documented — some trials exclude specific etiologies
- Prior and current antiseizure medication history (at least 2 failed medications) is typically required to confirm refractory status
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).